Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.

McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA.

Cancer. 2011 Dec 15;117(24):5461-8. doi: 10.1002/cncr.26171. Epub 2011 Jun 16.

2.

Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

Constantinidou A, Smith I.

Breast. 2011 Oct;20 Suppl 3:S158-61. doi: 10.1016/S0960-9776(11)70316-2. Review.

PMID:
22015286
3.

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.

4.

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.

Breast. 2013 Aug;22 Suppl 2:S152-5. doi: 10.1016/j.breast.2013.07.029. Review.

PMID:
24074778
5.

Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer.

Araki K, Saji S, Gallas M, Pegram M, Sasaki Y.

Breast Cancer. 2012 Apr;19(2):95-103. doi: 10.1007/s12282-011-0296-z. Epub 2011 Aug 24. Review.

PMID:
21863310
6.

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.

Del Mastro L, Lambertini M, Bighin C, Levaggi A, D'Alonzo A, Giraudi S, Pronzato P.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1391-405. doi: 10.1586/era.12.107. Epub 2012 Oct 16. Review.

PMID:
23072512
7.

Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials.

Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A.

Cancer Treat Rev. 2013 Feb;39(1):44-50. doi: 10.1016/j.ctrv.2012.03.009. Epub 2012 Apr 27. Review.

PMID:
22541668
8.

Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.

Kabe KL, Kolesar JM.

Am J Health Syst Pharm. 2006 Mar 15;63(6):527-33. Review.

PMID:
16522889
9.

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.

BMC Cancer. 2007 Aug 8;7:153. Review.

10.

[Update: adjuvant trastuzumab in HER2 positive breast cancer].

Tahover E, Sonnenblick A, Peretz T, Katz D.

Harefuah. 2012 Jan;151(1):37-42, 61. Review. Hebrew.

PMID:
22670500
11.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, Jönsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
12.

Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.

Bedard PL, Piccart-Gebhart MJ.

Clin Breast Cancer. 2008 Dec;8 Suppl 4:S157-65. doi: 10.3816/CBC.2008.s.012. Review.

PMID:
19158036
13.

Adjuvant trastuzumab therapy for HER2-positive breast cancer.

Jahanzeb M.

Clin Breast Cancer. 2008 Aug;8(4):324-33. doi: 10.3816/CBC.2008.n.037. Review.

PMID:
18757259
14.

Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review.

Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H.

Cancer Treat Rev. 2008 Oct;34(6):539-57. doi: 10.1016/j.ctrv.2008.03.013. Epub 2008 May 27. Review.

PMID:
18502589
15.

Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?

Joerger M, Thürlimann B, Huober J.

Ann Oncol. 2011 Jan;22(1):17-23. doi: 10.1093/annonc/mdq304. Epub 2010 Jun 20. Review.

PMID:
20566473
16.

Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing.

Hicks DG, Kulkarni S.

Arch Pathol Lab Med. 2008 Jun;132(6):1008-15. doi: 10.1043/1543-2165(2008)132[1008:TAATFE]2.0.CO;2. Review.

PMID:
18517261
17.

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S.

Oncologist. 2008 Jun;13(6):620-30. doi: 10.1634/theoncologist.2008-0001. Review.

18.

Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate.

Petrelli F, Barni S.

Med Oncol. 2011 Jun;28(2):401-8. doi: 10.1007/s12032-010-9460-0. Epub 2010 Mar 2. Review.

PMID:
20195801
19.

Patients with anti-HER2 responsive disease: definition and adjuvant therapies.

Burstein HJ.

Breast. 2011 Oct;20 Suppl 3:S132-4. doi: 10.1016/S0960-9776(11)70310-1. Review.

PMID:
22015280
20.

Management of small HER2-positive breast cancers.

Banerjee S, Smith IE.

Lancet Oncol. 2010 Dec;11(12):1193-9. doi: 10.1016/S1470-2045(10)70119-4. Review.

PMID:
21126688

Supplemental Content

Support Center